Skip to content
Pyridostigmine
Mestinon, Regonol (pyridostigmine) is a small molecule pharmaceutical. Pyridostigmine was first approved as Mestinon on 1982-01-01. It is used to treat drug-induced abnormalities and myasthenia gravis in the USA. It is known to target cholinesterase and acetylcholinesterase.
Download report
Favorite
Commercial
Therapeutic Areas
Therapeutic Area
MeSH
neoplasmsD009369
nervous system diseasesD009422
hereditary congenital and neonatal diseases and abnormalitiesD009358
immune system diseasesD007154
Trade Name
FDA
EMA
Mestinon, Regonol (generic drugs available since 2003-04-24)
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
Pyridostigmine bromide
Tradename
Company
Number
Date
Products
MESTINONBausch Health CompaniesN-009829 RX1982-01-01
1 products, RLD, RS
MESTINONBausch Health CompaniesN-009830 RX1982-01-01
1 products, RLD, RS
MESTINONBausch Health CompaniesN-011665 RX1982-01-01
1 products, RLD, RS
MESTINONBausch Health CompaniesN-015193 RX1982-01-01
1 products, RLD, RS
REGONOLSandozN-017398 RX1982-01-01
1 products
Show 1 discontinued
Labels
FDA
EMA
Brand Name
Status
Last Update
mestinonNew Drug Application2020-12-02
pyridostigmine bromideANDA2023-05-09
regonolNew Drug Application2021-04-01
Indications
FDA
EMA
Indication
Ontology
MeSH
ICD-10
drug-induced abnormalities—D000014—
myasthenia gravisEFO_0004991D009157G70.0
Agency Specific
FDA
EMA
No data
Patent Expiration
No data
ATC Codes
N: Nervous system drugs
— N07: Other nervous system drugs in atc
— N07A: Parasympathomimetics
— N07AA: Anticholinesterase parasympathomimetics
— N07AA02: Pyridostigmine
HCPCS
No data
Clinical
Clinical Trials
1 clinical trials
View more details
Mock data
Subscribe for the real data
Indications Phases 4
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Insecticide resistanceD007305———1—1
Indications Phases 3
No data
Indications Phases 2
No data
Indications Phases 1
No data
Indications Without Phase
No data
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
Drug common namePYRIDOSTIGMINE
INNpyridostigmine bromide
Description
Pyridostigmine is a medication used to treat myasthenia gravis. It is also used together with atropine to end the effects of neuromuscular blocking medication of the non-depolarizing type. It is typically given by mouth but can also be used by injection. The effects generally begin within 45 minutes and last up to 6 hours.
Classification
Small molecule
Drug classcholinesterase inhibitors (physostigmine type)
Image (chem structure or protein)
Structure (InChI/SMILES or Protein Sequence)
CN(C)C(=O)Oc1ccc[n+](C)c1
Identifiers
PDB—
CAS-ID155-97-5
RxCUI9000
ChEMBL IDCHEMBL1115
ChEBI ID8665
PubChem CID4991
DrugBankDB00545
UNII IDKVI301NA53 (ChemIDplus, GSRS)
Target
Agency Approved
No data
Alternate
BCHE
BCHE
ACHE
ACHE
Organism
Homo sapiens
Gene name
BCHE
Gene synonyms
CHE1
NCBI Gene ID
590
Protein name
cholinesterase
Protein synonyms
Acylcholine acylhydrolase, Butyrylcholine esterase, Choline esterase II, cholinesterase (serum) 2, cholinesterase 1, Pseudocholinesterase
Uniprot ID
P06276
Mouse ortholog
Bche (12038)
cholinesterase (Q543J3)
Variants
Clinical Variant
No data
Financial
No data
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Additional graphs summarizing 4,418 documents
View more details
Safety
Black-box Warning
No Black-box warning
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
158 adverse events reported
View more details